Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects
NCT02721069
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
175
Enrollment
INDUSTRY
Sponsor class
Conditions
Acute Repetitive Seizures
Breakthrough Seizures
Interventions
DRUG:
NRL-1
Sponsor
Neurelis, Inc.